Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) FCF Margin (2020 - 2026)

Journey Medical filings provide 6 years of FCF Margin readings, the most recent being 40.65% for Q4 2025.

  • On a quarterly basis, FCF Margin fell 5828.0% to 40.65% in Q4 2025 year-over-year; TTM through Dec 2025 was 20.52%, a 396.0% decrease, with the full-year FY2025 number at 20.32%, up 2345.0% from a year prior.
  • FCF Margin hit 40.65% in Q4 2025 for Journey Medical, down from 14.0% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 122.7% in Q3 2023 to a low of 108.28% in Q4 2023.
  • Median FCF Margin over the past 5 years was 19.93% (2021), compared with a mean of 17.47%.
  • Biggest five-year swings in FCF Margin: soared 16788bps in 2023 and later plummeted -13061bps in 2024.
  • Journey Medical's FCF Margin stood at 18.3% in 2021, then tumbled by -58bps to 28.86% in 2022, then plummeted by -275bps to 108.28% in 2023, then skyrocketed by 116bps to 17.63% in 2024, then plummeted by -331bps to 40.65% in 2025.
  • The last three reported values for FCF Margin were 40.65% (Q4 2025), 14.0% (Q3 2025), and 6.28% (Q2 2025) per Business Quant data.